India Cracks Down on Obesity Drug Marketing, Warns Pharma Firms Against Advertising Weight-Loss Medicines
Drug regulator cautions companies against direct or indirect promotion of prescription obesity drugs, including surrogate advertising and influencer campaigns
- By PharmaNews Live Desk
- New Delhi
- Mar 12, 2026
India’s drug regulator has issued a strong advisory warning pharmaceutical companies against directly or indirectly promoting prescription weight-loss medicines to the public, amid growing marketing campaigns around obesity treatments.
The Central Drugs Standard Control Organisation (CDSCO), in an advisory dated March 11, cautioned manufacturers, importers and marketing authorisation holders to strictly comply with provisions of the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945, which prohibit the advertising of prescription medicines to consumers.
The advisory was issued by the Drugs Controller General of India (DCGI), Rajeev Raghuvanshi, following concerns that some pharmaceutical companies may be using indirect promotional strategies to create demand for obesity drugs.
Surrogate Advertising and “Awareness Campaigns” Under Scrutiny
Regulators have specifically warned companies against indirect or “surrogate” advertising practices, including disease-awareness campaigns that may promote prescription drugs without naming them.
According to the CDSCO advisory, promotional activities conducted under the guise of awareness drives or digital outreach could still be treated as marketing for prescription medicines.
The regulator stated that “any promotional activity, including so-called disease-awareness campaigns that function as surrogate advertisements for prescription medicines, will be viewed seriously.”
Officials also warned that campaigns involving influencer engagement, celebrity endorsements or corporate branding that create product recall could violate drug marketing rules.
Misleading Claims Could Trigger Regulatory Action
The advisory further cautioned companies against marketing claims that exaggerate the effectiveness of obesity drugs or present them as quick solutions for weight loss.
According to the regulator, advertisements that exaggerate therapeutic efficacy, promise guaranteed weight-loss outcomes, or downplay lifestyle changes could be treated as misleading promotion and attract regulatory action.
Authorities also emphasised that such drugs must only be prescribed by registered medical practitioners and used strictly according to approved indications.
“Prescription drugs, including GLP-1 receptor agonists, are required to be prescribed by registered medical practitioners,” the DCGI said.
Growing Market for Obesity Drugs Raises Regulatory Concerns
The advisory comes at a time when demand for weight-loss medications is rising globally and pharmaceutical companies are increasingly targeting the Indian market.
Newer drugs belonging to the GLP-1 class — used for diabetes and obesity management — have gained significant attention worldwide. Medicines such as semaglutide and tirzepatide have entered the Indian market in recent years, with more generics expected as patents expire.
As competition intensifies, companies have stepped up public messaging around obesity and metabolic disorders, often through multimedia awareness campaigns and digital platforms.
However, regulators have reiterated that public communication around prescription medicines must remain compliant with Indian drug laws.
Obesity Requires Comprehensive Management, Says Regulator
The CDSCO advisory also stressed that obesity is a complex medical condition that requires long-term management and lifestyle interventions.
The regulator noted that “obesity is a chronic metabolic condition requiring comprehensive management, including lifestyle interventions.”
Authorities cautioned companies not to portray pharmaceutical therapy as a substitute for preventive healthcare measures such as healthy diet, exercise and behavioural changes.
With the obesity drug market expanding rapidly, India’s latest move signals tighter oversight of pharmaceutical marketing practices to prevent misleading claims and protect consumers from inappropriate use of prescription medicines.